15Oct 2022
Single‐fraction prostate‐specific membrane antigen positron emission tomography‐ and multiparametric magnetic resonance imaging‐guided stereotactic body radiotherapy for prostate cancer local recurrences

Single‐fraction prostate‐specific membrane antigen positron emission tomography‐ and multiparametric magnetic resonance imaging‐guided stereotactic body radiotherapy for prostate cancer local recurrences

To analyse the efficacy and safety of focal prostate‐specific membrane antigen positron emission tomography (PSMA‐PET)‐ and multiparametric magnetic resonance imaging (mpMRI)‐guided single‐fraction stereotactic body radiotherapy (SBRT) for the treatment of prostate cancer (PCa) local recurrences. While the available data for SBRT in the PCa local recurrence setting describe outcomes for fractionated irradiations, the findings of this first analysis of single‐fraction, PSMA‐PET‐ and mpMRI‐guided focal SBRT are encouraging. Such treatment appears to be a safe, efficient, and time‐saving therapy, even in intensively pretreated patients. Recurrence‐directed treatments can delay the use of ADT and could avoid prostate bed irradiation in selected patients.

  • #urology

Like

Save

Share